Bioheart (BHRT.OB) raises $4M
January 25th, 2011
No comments
BHRT.OB entered into an agreement with AnC Bio Holdings, a South Korean biomedical company for a $4M equity investment. Read more…
Archive
Archive for the ‘Stem Cell Technology’ Category
Athersys (ATHX) Retail Investor Conferences
January 24th, 2011
No comments
ATHX‘s 1/11/11, Retail Investor Conferences.com presentation is available for on-demand viewing. Read more…
CIRM, Recruits Amgen’s Medical Director for R&D
January 24th, 2011
No comments
California’s stem cell research funding agency names an Amgen executive medical director to head R&D. Read more…
Categories: Stem Cell Research, Stem Cell Technology
BrainStorm (BCLI.OB), New COO and acting CEO
January 24th, 2011
No comments
BCLI.OB recruited Adrian Harel, PhD as its new COO and acting CEO. Read more…
Categories: Nasdaq: BCLI.OB, New COO and acting CEO, Stem Cell Technology
Cytori Therapeutics (CYTX), Clinical Experience shows No Increased Risk
January 24th, 2011
No comments
No evidence of increased risk of development, metastasis or recurrence of breast cancer Read more…
Aastrom Biosciences (ASTM) Downgraded to Neutral
January 24th, 2011
No comments
National Securities downgraded shares of Aastrom Biosciences (ASTM) to a “NEUTRAL” rating Read more…
Categories: NASDAQ: ASTM, National Securities Downgrade, Stem Cell Technology
Cytori Therapeutics (CYTX), Post-Hoc APOLLO Study
January 21st, 2011
No comments
Adipose-Derived Regenerative Cell (ADRC) therapy associated with reduction in arrhythmia in acute heart attack patients. Read more…
Categories: APOLLO study, NASDAQ: CYTX, Stem Cell Technology
Aastrom Biosciences (ASTM), Skepticism Abounds
January 20th, 2011
No comments
Previously reported interim results from the US Phase 2b RESTORE-CLI clinical trial Read more…
Categories: Aastrom Biosciences, NASDAQ: ASTM, Stem Cell Technology
Aastrom Biosciences (ASTM), IMPACT-DCM Clinical Results presented
January 20th, 2011
No comments
US Phase 2 IMPACT-DCM clinical trial results were reviewed at The Sixth International Conference on Cell Therapy for Cardiovascular Disease in NYC, NY, Read more…
NeoStem (AMEX: NBS) acquires Progenitor Cell Therapy
January 20th, 2011
No comments
NBS and Progenitor Cell Therapy (PCT) closed their merger transaction. Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.